Gilead Sciences, Inc. reported a total revenue of $29.4 billion for the fiscal year ending December 31, 2025, marking a 2% increase from $28.8 billion in 2024. The company's net income saw a significant rise to $8.5 billion, compared to $480 million in the previous year, resulting in diluted earnings per share of $6.78, up from $0.38. This substantial increase in profitability was primarily attributed to the absence of a $3.8 billion in-process research and development (IPR&D) expense related to the acquisition of CymaBay Therapeutics in 2024, as well as lower impairment charges and higher revenues from product sales, particularly in the HIV and liver disease segments.
In 2025, Gilead launched Yeztugo, the first twice-yearly HIV pre-exposure prophylaxis (PrEP) option in the U.S., and expanded the market share of Livdelzi for treating primary biliary cholangitis. The company also made strategic acquisitions, including Interius BioTherapeutics for approximately $350 million and announced plans to acquire Arcellx for an estimated $7 billion, which will enhance its oncology pipeline. Gilead's research and development efforts remain robust, with over 50 clinical-stage programs across its core therapeutic areas, including HIV, oncology, and inflammation.
Operationally, Gilead's HIV product sales increased by 6% to $20.8 billion, driven by strong demand for Biktarvy and Descovy. However, sales of Veklury, its COVID-19 treatment, decreased by 49% to $911 million due to lower hospitalization rates. The company reported a total employee headcount of approximately 17,000 as of December 31, 2025, reflecting its commitment to maintaining a skilled workforce to support its ongoing research and development initiatives.
Looking ahead, Gilead anticipates continued growth in product sales, particularly in its HIV business, although it expects some offset from policy-related developments in the U.S. and a decline in Veklury sales. The company plans to maintain its focus on disciplined operating expense management while investing in its R&D pipeline and pursuing strategic partnerships to drive innovation and growth. Gilead's financial outlook remains positive, with expectations for further updates on clinical trials and regulatory submissions in 2026.
About GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for unmet medical needs. Its core areas include virology, oncology, and inflammation, with key products for HIV, hepatitis, COVID-19, and cancer. Operating globally, Gilead emphasizes first-in-class therapies, strategic collaborations, and a strong patent portfolio to maintain competitive advantage and improve patient outcomes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.